This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Medlab Clinical 과거 수익 실적

과거 기준 확인 0/6

Medlab Clinical의 수입은 연평균 -18.9%의 비율로 감소해 온 반면, Biotechs 산업은 수입이 연평균 12.6%의 비율로 증가했습니다. 매출은 연평균 19.2%의 비율로 감소해 왔습니다.

주요 정보

-18.9%

수익 성장률

-7.9%

EPS 성장률

Biotechs 산업 성장	9.6%
매출 성장률	-19.2%
자기자본 수익률	-108.3%
순이익	-541.7%
최근 수익 업데이트	30 Jun 2022

최근 과거 실적 업데이트

Recent updates

Shareholders May Be More Conservative With Medlab Clinical Limited's (ASX:MDC) CEO Compensation For Now

Oct 06

수익 및 비용 분석

Medlab Clinical 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

ASX:MDC 수익, 비용 및 수입 (AUD Millions )
날짜	수익	수익	G+A 비용	R&D 비용
30 Jun 22	2	-8	12	2
31 Mar 22	1	-9	9	1
31 Dec 21	4	-12	11	1
30 Sep 21	4	-12	11	2
30 Jun 21	1	-10	11	2
31 Mar 21	1	-10	10	2
31 Dec 20	1	-11	9	2
30 Sep 20	2	-12	9	2
30 Jun 20	3	-13	10	2
31 Mar 20	4	-12	10	2
31 Dec 19	4	-12	11	2
30 Sep 19	5	-10	10	1
30 Jun 19	5	-8	10	1
31 Mar 19	5	-7	8	1
31 Dec 18	5	-6	7	0
30 Sep 18	4	-5	7	0
30 Jun 18	4	-5	6	0
31 Mar 18	4	-4	6	0
31 Dec 17	5	-4	6	0
30 Sep 17	5	-4	5	0
30 Jun 17	4	-4	5	0
31 Mar 17	4	-4	5	0
31 Dec 16	4	-4	4	0
30 Sep 16	3	-4	4	0
30 Jun 16	3	-3	4	0

양질의 수익: MDC 은(는) 현재 수익성이 없습니다.

이익 마진 증가: MDC 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: MDC 은(는) 수익성이 없으며 지난 5년 동안 연간 18.9% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 MDC 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: MDC 은(는) 수익성이 없어 지난 해 수익 성장을 Biotechs 업계( 3.4% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: MDC 현재 수익성이 없기 때문에 마이너스 자본 수익률( -108.25% )을 갖습니다.

This company listing is no longer active

Medlab Clinical 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: Revenues exceed analyst expectations

Full year 2021 earnings released: AU$0.042 loss per share (vs AU$0.059 loss in FY 2020)

First half 2021 earnings released: AU$0.019 loss per share (vs AU$0.033 loss in 1H 2020)

Full year earnings released - AU$0.059 loss per share

Recent updates

Consensus EPS estimates upgraded to AU$2.29 loss, revenue downgraded

Consensus forecasts updated

Price target decreased to AU$18.84

Medlab Announces Interim Readout of Rwe Medcare Study

Medlab Clinical Limited Receives UK Import Permission from MHRA for Nanabis

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Medlab Clinical Limited Provides NanoCelle Nasal RNA (Nucleid Acid) Program Update

Medlab Clinical Limited Provides NanaBis and NanoCBD Clinical Development Update

Less than half of directors are independent

Medlab Clinical Limited Announces the Resignation of Laurence McAllister as Non-Executive Director

Full year 2022 earnings: Revenues exceed analyst expectations

Medlab Clinical Limited, Annual General Meeting, Sep 30, 2022

Medlab Clinical Ltd Announces the European Patent Office Has Formalised ACCEPTANCE of the Depression Patent, and Within the Next 2-3 Months Will Be Granted

Medlab Clinical Limited Appoints Mohit Gupta as an Independent Non-Executive Director, Effective August 8, 2022

Medlab Clinical Ltd Updates Shareholders on the Progress of Our NanoCelle NanaBis Program

Medlab Clinical Ltd Announces Update on Progression of NanoCelle NASAL COVID-19 Vaccine Program

Less than half of directors are independent

Medlab Clinical Ltd Announces Update on NanoCBDTM

Medlab Clinical Ltd Announces the Receipt of "Favorable Opinion" Status from the UK Research Ethics Committee for the Forthcoming Nanabistm Phase 3 Trial, with No Additional Conditions or Submission Required

Shareholders May Be More Conservative With Medlab Clinical Limited's (ASX:MDC) CEO Compensation For Now

Is Medlab Clinical (ASX:MDC) In A Good Position To Invest In Growth?

Full year 2021 earnings released: AU$0.042 loss per share (vs AU$0.059 loss in FY 2020)

Medlab Receives Phase 3 NanaBi Trials Approval from the Australian Government, with Clinical Trials Number for Cancer Bone Pain

Australian Ethics Grants Approval for Medlab's NanaBisTM PIII Australian Sites

CFO, Company Secretary & COO has left the company

Medlab Clinical Limited announced that it expects to receive AUD 15 million in funding

Medlab Clinical Limited Appoints Cheryl Maley as an Independent Non-Executive Director

First half 2021 earnings released: AU$0.019 loss per share (vs AU$0.033 loss in 1H 2020)

What We Learned About Medlab Clinical's (ASX:MDC) CEO Pay

Medlab Executes Australian Exclusive Non-Binding Heads of Agreement with Arrotex Australia Group Australia Pty Ltd

Medlab Clinical Limited Receives Positive Depression Trial Prelim Results

New 90-day high: AU$0.36

Medlab Clinical Announces US FDA Grants Investigational New Drug (IND) Status for Nanabistm

Medlab Clinical (ASX:MDC) Share Prices Have Dropped 69% In The Last Three Years

Medlab Clinical Provides an Update on Clinical and Pre-Clinical Programs Currently Underway

Medlab Clinical Limited Announces NanaBis Observational Study Progression Report

New 90-day high: AU$0.26

Medlab Clinical Limited (ASX:MDC) Is Expected To Breakeven In The Near Future

Medlab Clinical Limited Announces NanaBisTM PIII Trial Launching in the Uk with Support from the National Institute for Health Research

New 90-day high: AU$0.21

Full year earnings released - AU$0.059 loss per share

Medlab Clinical Limited has completed a Follow-on Equity Offering in the amount of AUD 1.570476 million.

Medlab Clinical Limited announced that it has received AUD 5.397603 million in funding

수익 및 비용 분석

수익 및 매출 내역

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

자기자본 수익률

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기